RADX
Radiopharm Theranostics Limited
Set alert
- YTD
- -79.31%
- 1 year
- -79.11%
- Open
- 1.09
- Prev close
- 1.12
- Mkt cap
- 16.96M
- Vol
- 8.92K
- Avg vol
- 56.66K
- EPS
- -3.64
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.08
- High
- 1.16
- Forward P/E
- 0.00
- Beta
- 0.85
- Short ratio
- 0.00
- Inst. own
- 0.00%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 7.67
- 200-d avg
- 7.67
- 1y target
- 0.00
Key statistics
- Market cap
- 0
- Enterprise value
- 9.52B
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 69.02
- EPS (TTM)
- -0.08
- Beta
- 0.85
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 1.96M
- Revenue growth
- 0.00%
- Free cash flow
- -12.04M
- Total cash
- 18.58M
- Total debt
- 0
- Return on equity
- -131.49%
- Shares outstanding
- 0
- Short % of float
- 0.00%
- 50-day average
- 7.67
- 200-day average
- 7.67
Analyst view
Consensus: none
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
About Radiopharm Theranostics Limited
Radiopharm Theranostics Limited engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs. It develops RAD 204, a programmed death-ligand 1 (PD-L1) for the treatment of non-small cell lung cancer (NSCLC); RAD 202, a human epidermal growth factor receptor 2 (HER2) to treat breast cancer and other solid tumors; and RAD 301, a diagnostic radiopharmaceutical targeting avß6 integrin in pancreatic ductal adenocarcinoma patients. The company also develops RAD 302, an avß6-integrin targeting agent for the treatment of multiple cancer types; RAD 101 and RAD 102 for brain metastases; RAD 402 to treat advanced prostate cancer; and RV01 for multiple solid tumors. The company was incorporated in 2021 and is based in Carlton, Australia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Australia
- Website
- radiopharmtheranostics.com
News
- 12 Health Care Stocks Moving In Friday's After-Market Session
- Radiopharm Theranostics Announces Completion Of EOP2 Meeting With FDA Regarding RAD101, Investigational Radiopharmaceutical Imaging Agent For Detection Of Brain Metastases
- 12 Health Care Stocks Moving In Monday's After-Market Session
- Radiopharm Says Data From Interim Analysis Of Phase 2b Imaging Clinical Trial Of 18F-RAD101 In Participants With Suspected Recurrent Brain Metastases From Solid Tumors Selected For Presentation At SNO26 Annual Meeting
- 12 Health Care Stocks Moving In Friday's Pre-Market Session
- 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- Radiopharm Theranostics Shares Data From Phase 1 Imaging Trial of RAD 301 In Healthy Volunteers And Subjects With Pancreatic Ductal Adenocarcinoma
- Radiopharm Theranostics Announces Positive Data from the Phase 1 Imaging Trial of RAD301 in Patients with Pancreatic Ductal Adenocarcinoma
- Radiopharm Doses First Patient In Second Cohort Of Its First-In-Human Phase 1/2a Clinical Trial Of RV-01 In Patients With B7-H3 Expressing Tumors
- Radiopharm Theranostics Doses First Patient in Second Cohort of Phase 1/2a Clinical Trial of BetaBart (RV-01) in B7-H3 Expressing Solid Tumors
Your note
Sign in to keep a note on RADX — it syncs with the Stock Master app.